Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasDiseaseNHL, B-cell type, transformed LymphomaSubgroupRichter transformation, DLBCLICD10MeSHSequenceNIVO3, CLL (Richter Transformation), C1 (PID2851) -|- NIVO3/IBRU420, C2+ (PID2852)ChemotherapyChemo-substanceAcalabrutinibCyclophosphamideIbrutinibNivolumabPembrolizumabPirtobrutinibChemo-substanceAcalabrutinibCyclophosphamideIbrutinibNivolumabPembrolizumabPirtobrutinibChemo-substanceAcalabrutinibCyclophosphamideIbrutinibNivolumabPembrolizumabPirtobrutinibChemo-substanceAcalabrutinibCyclophosphamideIbrutinibNivolumabPembrolizumabPirtobrutinibNo. Substances12 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimGranisetronSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimGranisetronSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimGranisetronSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimGranisetronNo. Substances123Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationFirst lineseveral possibleTherapy phasePre-phaseTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlArthalgiaAtrial FibrillationBleedingDiarrheaDyspneaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHypercalcemiaHyperthyroidismHypokalemiaHypothyroidismIncrease in lipaseInfectionsNeutropeniaPleural EffusionPneumoniaPneumonitisRashSepsisThrombocytopenia below 50 000/µlUpper Respiratory Tract Infection only studiesPublicationAuthorAl-Sawaf OArmand PEyre TAJain NWierda WGDiseaseCLL (Richter Transformation)CLL (Richter Transformation), ECOG 0-1CLL (Richter Transformation), therapierefraktär/rezidiviert oder Erstlinie mit del(17p)OriginCancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UKCenter for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Germany, RT1 trialDana-Farber Cancer Institute, Boston, USA, KEYNOTE-170 trialThe University of Texas, MD Anderson Cancer Center, Houston, USA, BRUIN trialThe University of Texas MD Anderson Cancer Center, HoustonProtocols in Revision 6 protocols foundProtocols under revision.Acalabrutinib 200, Chronic Lymphocytic Leukemia, Richter Transformation (PID2848 V1.0)Cyclophosphamide 200, Pre-phase, Chronic Lymphocytic Leukemia, Richter Transformation (PID2853 V1.0)Nivolumab 3 / Ibrutinib 420, Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 2+ (PID2852 V1.0)Nivolumab 3, Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 1 (PID2851 V1.0)Pembrolizumab 200, Chronic Lymphocytic Leukemia, Richter Transformation (PID2850 V1.0)Pirtobrutinib 200, Chronic Lymphocytic Leukemia, Richter Transformation (PID2849 V1.0)
